Evidence strategy.
Discernment coaching.
Senior counsel for biopharma value and access.
Confidential counsel for leaders at their most consequential moments.
.png){kind=icon}
When the stakes are
too high for misalignment
Senior biopharma leaders, and the leaders inside them, call on me when the stakes around evidence, access, or career transitions are too high to navigate alone.
Your value story is not landing with payers
When the evidence exists but the narrative does not connect, access decisions stall. I translate evidence into payer-relevant value communication grounded in U.S. and EU payer and reimbursement strategy.
Your evidence plan exists; the cross-functional behavior it should drive does not
Siloed evidence plans create costly gaps at HTA submission, and the deeper trap is treating the plan as the destination rather than the starting point. A rigorous plan is demanding work; it earns its value only when it drives aligned cross-functional behavior. I build integrated strategies that align clinical, HEOR (health economics and outcomes research), real-world, medical, and patient-focused evidence around a unified value narrative, alongside the operating cadence that keeps teams aligned to the decisions the evidence is built to inform.
EU HTA or JCA readiness is uncertain
New assessment frameworks demand new evidence strategies. I bring global perspective and HTA (health technology assessment) experience to prepare your dossier and your team for Joint Clinical Assessment (JCA) submission.
You are at an inflection point that demands discernment
Leaders at consequential inflection points rarely have a confidential thinking partner with the depth to hold the moment. The Discernment Practice provides sustained coaching for the decisions that shape a leader’s next chapter.
Fractional Strategic Advisory
Ongoing embedded partnership with your evidence or value team.
The judgment of a VP-level leader without the overhead of a full-time hire.
Project Intensives
Focused, time-bound engagements around specific deliverables: HTA readiness reviews, integrated evidence plan development, PFDD (patient-focused drug development) strategy design.
The Discernment Practice
Confidential coaching for leaders at consequential inflection points. Sustained retainer engagement.
Speaking and Facilitation
Conference keynotes, panel moderation, and executive workshops on evidence strategy, real-world evidence, and the business case for patient-centricity.
.avif)
Speaking and expert contributions
With more than one hundred publications, invited presentations, and media appearances across ISPOR, DIA, HTAi, Patients as Partners, Patient Focused Medicines Development, and other leading forums, I bring evidence-informed perspective to complex topics that matter to senior biopharma audiences.
Patients as Partners
Engaging Internal Stakeholders to Embed Engagement
Patient Focused Medicines Development
A Pioneering Opportunity: Piloting the First How-To Guide
ISPOR Educational Webinar
A Novel Approach to Selecting Treatment Sequences
National Alliance for Caregiving
Family Caregiver Roles in Medical Product Development
DIA Annual Meeting
Industry Cross-Functional Collaborations Optimizing Market Access
Scrip Award
Best Use of Real-World Evidence
Brandon Hall Gold Award
PFDD Learning & Development
Co-Chair, Caregiver Pathways Task Force
A National Alliance for Caregiving and LEAD Coalition Initiative
.avif)
Frequently Asked Questions
I work with senior leaders in biotech and biopharma, typically SVPs, Chief Medical Officers, and C-suite executives, and with the leaders inside those organizations who are navigating their most consequential career and team transitions. On the evidence side, I am most useful to teams building or strengthening their evidence strategy function ahead of a U.S. value or access decision, an EU health technology assessment (HTA) submission, or a Joint Clinical Assessment (JCA) filing. On the coaching side, I work with leaders at inflection points where the right move is not obvious and the cost of getting it wrong is high.
Evidence strategy is the discipline of designing, generating, and translating the data and narrative that determine whether a medicine reaches patients and earns the access it deserves. The work spans the integration of health economics and outcomes research (HEOR), real-world evidence, clinical, and medical streams around a unified value narrative, and the translation of that narrative for payers, health technology assessment (HTA) bodies, healthcare providers, and patients. Patient-focused evidence belongs at the core of the value narrative, not at its edges, and the strategy must build around it from the start rather than appending it at submission. The decisions that shape evidence are made long before the moment of submission. The strategy is the architecture that holds those decisions together.
On the evidence side, the work centers on value demonstration strategy, payer and reimbursement strategy, integrated evidence plan design, health technology assessment (HTA) and Joint Clinical Assessment (JCA) readiness, and patient-focused drug development (PFDD) capability building. On the coaching side, The Discernment Practice centers on career inflection, role transition, post-acquisition integration, team architecture, and the leadership decisions where strategy, identity, and legacy converge.
Two pillars under one principle. The decisions that determine outcomes are made long before the obvious moment, whether the outcome is patient access or a leader’s next chapter. My evidence work brings twenty years across biopharma and consulting, with deepest experience in neurology, immunology, and rare disease across U.S. payer and EU health technology assessment environments. My coaching is The Discernment Practice, grounded in two decades of developing leaders and the senior seats where those decisions are made. The combination is uncommon in either field.
I work with a small number of clients at any given time, which protects the depth and full strategic attention that every engagement requires. Capacity for new evidence advisory and coaching engagements opens on a rolling basis. The introductory conversation is where we determine fit and timing together.
I am based in the Greater Boston area and work with clients across the United States, the European Union, and the United Kingdom. Most engagements are conducted remotely, with periodic in-person sessions when the work calls for it.
